Aequus Announces Delay in Filing Annual Financial Statements
May 02, 2022 20:30 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual...
Aequus Announces Short Term Loan
May 02, 2022 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with...
Aequus Announces Director Resignation
April 22, 2022 16:30 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and...
Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada
January 24, 2022 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension...
Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
January 11, 2022 09:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication
January 06, 2022 09:00 ET
|
Aequus Pharmaceuticals
Health Canada Submission of Preservative-Free Prescription ‘Zimed PF’ Accepted for Screening VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS,...
Aequus Reports Third Quarter 2021 Financial Highlights
November 03, 2021 05:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Reports Second Quarter 2021 Financial Highlights
August 30, 2021 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise
August 25, 2021 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a speciality pharmaceutical company, is pleased to announce that Dr....
Aequus and reVision to Collaborate on Stargardt Disease Program
August 17, 2021 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”)...